SION

MKT CAP:$2B

Sionna Therapeutics, Inc.

Market Cap

$2B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$37.98-$1.23 (-3.14%)

Apr 24, 2026

Company Details

Sionna Therapeutics, Inc. is a biopharmaceutical company. The Company provides treatment paradigm for cystic fibrosis patients by developing medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator.

CEO

Michael Cloonan

IPO Date

Feb 7, 2025

Website

www.sionnatx.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$75M

EPS (Diluted)

-$1.70

Free Cash Flow

-$67M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

Q1 2026

May 11, 2026

PENDING

FY 2025

Mar 2, 2026

$0EPS -$1.88

Q4 2025

Mar 2, 2026

$0EPS -$0.46

Q3 2025

Nov 5, 2025

$0EPS -$0.46

Q2 2025

Aug 11, 2025

$0EPS -$0.41

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q4 23	$0	$0	-$13M
Q1 24	$0	$0	-$13M
Q2 24	$0	-$166.0K	-$11M
Q3 24	$0	$0	-$28M
Q4 24	$0	$0	-$18M
Q1 25	$0	$0	-$20M
Q2 25	$0	-$147.0K	-$22M
Q3 25	$0	-$100.0K	-$24M
Q4 25	$0	-$152.0K	-$24M

Operating Cash Flow

Quarter	Operating CF	Free CF
Q4 23	-$7M	-$8M
Q1 24	-$13M	-$13M
Q2 24	-$10M	-$10M
Q3 24	-$18M	-$18M
Q4 24	-$12M	-$12M
Q1 25	-$16M	-$16M
Q2 25	-$18M	-$18M
Q3 25	-$15M	-$15M
Q4 25	-$17M	-$17M

Capital Expenditures

Quarter	CapEx
Q4 23	$122.0K
Q1 24	$0
Q2 24	$0
Q3 24	$0
Q4 24	$0
Q1 25	$86.0K
Q2 25	$0
Q3 25	$87.0K
Q4 25	$204.0K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q4 24	—	+44.0%
Q1 25	—	+49.5%
Q2 25	—	+94.0%
Q3 25	—	-14.9%
Q4 25	—	+30.2%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q4 23	$572.0K	—
Q1 24	$647.0K	—
Q2 24	$971.0K	—
Q3 24	$1M	—
Q4 24	$1M	—
Q1 25	$2M	—
Q2 25	$3M	—
Q3 25	$3M	—
Q4 25	$4M	—

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q4 23	$10M	$3M	—
Q1 24	$10M	$3M	—
Q2 24	$8M	—	$3M
Q3 24	$25M	$4M	—
Q4 24	$14M	$4M	—
Q1 25	$14M	$6M	—
Q2 25	$15M	$7M	—
Q3 25	$16M	—	$8M
Q4 25	$15M	$10M	—

War Chest

Quarter	Cash	Short-term Investments	Total
Q4 23	$39M	$0	$39M
Q3 24	$36M	$102M	$137M
Q4 24	$38M	$110M	$148M
Q1 25	$83M	$187M	$270M
Q2 25	$41M	$222M	$263M
Q3 25	$51M	$197M	$248M
Q4 25	$58M	$177M	$236M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q4 23	44M	—	—
Q1 24	44M	0.0%	—
Q2 24	44M	0.0%	—
Q3 24	44M	0.0%	—
Q4 24	44M	0.0%	0.0%
Q1 25	44M	-0.1%	-0.1%
Q2 25	44M	+0.1%	+0.0%
Q3 25	44M	+0.8%	+0.8%
Q4 25	40M	-10.1%	-9.4%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q4 23	—	—
Q1 24	—	—
Q2 24	—	—
Q3 24	—	—
Q4 24	$0	106K
Q1 25	$0	106K
Q2 25	$0	106K
Q3 25	$0	106K
Q4 25	$0	106K

Revenue / Employee